

Use of Neurophysiological Markers to Design and Enrich Clinical Trials in Psychiatric Disorders

## Chairs:

Jenicka Engler, PsyD Atul Mahableshwarkar, MD, DFAPA

# Disclosures

#### **Atul Mahableshwarkar:**

Employee of Cybin IRL Stock ownership in Johnson & Johnson, GlaxoSmithKline, and Emalex

## Jenicka Engler:

Full time employee of Cronos, an IQVIA business. Dr. Engler also receives authorship royalties from the Euthymic Baseline Assessment for Depression (EBAD) and Anhedonia Interview Rating Scales (AIRS).



# **Speakers**

Manish Jha, MBBS
Gahan Pandina, PhD
Luca Pani, MD
Adam Savitz, MD, PhD
Jenicka Engler, PsyD
Atul Mahableshwarkar, MD, DFAPA